General Services NA, Inc
drug research and development
General Services of North America, Inc. is involved in developing several new drugs - of the general family of Dopamine receptor (D2) antagonist - for the treatment of Parkinson. This research has now reached the stage where we need to purchase kilograms of alpha-ERGOCRYPTINE. We are only interested in Pharmaceutical grade (98%)material.
This purchase will only be used in the chemical research laboratory and will not be used on animals or humans.